Showing 1251 results
-
Press release /Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline Neuropathic pain is a chronic…
-
Press release /In the FUTURE 2 study, secukinumab demonstrated rapid onset of action, was significantly superior to placebo in improving signs and symptoms of psoriatic arthritis (PsA), with efficacy sustained…
-
Press release /Farydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with…
-
Press release /Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US customers…
-
Press release /Strong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
-
Press release /Innovative AcrySof® IQ PanOptix® trifocal intraocular lens design to improve near to intermediate vision and increase independence from glasses More than three million cataract surgeries…
-
Press release /Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…
-
Press release /Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in…
-
Press release /Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an…
-
Press release /Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus…